James Cornwall has close to 30 years professional experience in the pharmaceutical and CRO industries, working across a range of disciplines including academic research, clinical development, corporate development and investing. He works with the investment team in the London, Boston and Menlo Park offices to source and evaluate new clinical co-development (CCD) investment opportunities and supports existing CCD investments.
Prior to joining Abingworth, James was Chief Business Officer at Nuvelution, a specialist CCD investment company. Before Nuvelution, he was with IQVIA as head of corporate development and regional board member for the Asia Pacific region, and previously with NovaQuest, Quintiles internal investment group, where he led multiple investments in Europe and the USA. James started his career in clinical research with positions of increasing responsibility at GSK, before moving to Quintiles in global operations and sales roles. He is a founder at Ninnion LLC and President US-Asia Pharma Advisory LLC.
James has a BSc in Pharmacology and a PhD in Neuropharmacology from the University of Bristol, UK, where he published over twenty peer reviewed papers. He completed postgraduate training in Executive Leadership, from the University of North Carolina Kenan Flagler Business School.